Literature DB >> 19326100

The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms?

Daria Peleg-Raibstein1, Benjamin K Yee, Joram Feldon, Jonas Hauser.   

Abstract

RATIONALE: A sensitized dopamine system may be linked to the genesis of psychotic symptoms in schizophrenia. Following withdrawal from amphetamine exposures, psychotic-like traits have been robustly demonstrated, but the presence of cognitive/mnemonic deficits remains uncertain.
METHODS: Adult male Lewis and Fischer rats, differing in cognitive performance, were exposed intermittently to escalating doses of amphetamine over 5 weeks. This was effective in producing behavioral sensitization to a subsequent amphetamine challenge. Following 27 days of drug withdrawal, the animals were assessed in Pavlovian conditioning, object recognition, and spatial working memory. In addition, prepulse inhibition (PPI), spontaneous motor activity, and anxiety-like behavior were measured.
RESULTS: Amphetamine pretreatment induced behavioral sensitization in both rat strains similarly. Working memory was enhanced in Fischer but not Lewis rats following withdrawal. Spontaneous novel object preference was enhanced in sensitized Fischer rats, but was impaired in sensitized Lewis rats, thus effectively reversing the strain difference in non-sensitized controls. In contrast, Pavlovian fear conditioning remained unaffected and so were anxiety-like behavior, open field activity, and PPI.
CONCLUSION: The face validity of the amphetamine withdrawal model for cognitive deficits was limited to the object recognition memory impairment observed in sensitized Lewis rats. Yet, the possibility that enhancing dopaminergic neurotransmission may facilitate object recognition and spatial working memory performance was demonstrated in sensitized Fischer rats. Identification of the mechanisms underlying such strain-dependent effects would be instrumental in the further specifications of the construct validity, and therefore the limitations and potential of the amphetamine sensitization model of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326100     DOI: 10.1007/s00213-009-1514-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  94 in total

1.  Altered responsiveness of medial prefrontal cortex neurons to glutamate and dopamine after withdrawal from repeated amphetamine treatment.

Authors:  J D Peterson; M E Wolf; F J White
Journal:  Synapse       Date:  2000-06-15       Impact factor: 2.562

2.  Selective nucleus accumbens core lesions enhance dizocilpine-induced but not apomorphine-induced disruption of prepulse inhibition in rats.

Authors:  Helen H J Pothuizen; Ken R Neumann; Joram Feldon; Benjamin K Yee
Journal:  Behav Pharmacol       Date:  2006-03       Impact factor: 2.293

3.  Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal.

Authors:  Holger Russig; Carol A Murphy; Joram Feldon
Journal:  Neuropsychopharmacology       Date:  2002-06       Impact factor: 7.853

Review 4.  Working memory dysfunction in schizophrenia.

Authors:  P S Goldman-Rakic
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1994       Impact factor: 2.198

5.  Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats.

Authors:  P E Paulson; D M Camp; T E Robinson
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 6.  Should schizophrenia be treated as a neurocognitive disorder?

Authors:  M F Green; K H Nuechterlein
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

7.  Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex.

Authors:  Paul J Fletcher; Catherine C Tenn; Zoë Rizos; Vedran Lovic; Shitij Kapur
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

Review 8.  Imaging dopamine transmission in schizophrenia. A review and meta-analysis.

Authors:  M Laruelle
Journal:  Q J Nucl Med       Date:  1998-09

9.  Glial fibrillary acidic protein and the mesolimbic dopamine system: regulation by chronic morphine and Lewis-Fischer strain differences in the rat ventral tegmental area.

Authors:  D Beitner-Johnson; X Guitart; E J Nestler
Journal:  J Neurochem       Date:  1993-11       Impact factor: 5.372

10.  The Effects of dizocilpine and phencyclidine on prepulse inhibition of the acoustic startle reflex and on prepulse-elicited reactivity in C57BL6 mice.

Authors:  Benjamin K Yee; D L Tilly Chang; Joram Feldon
Journal:  Neuropsychopharmacology       Date:  2004-10       Impact factor: 7.853

View more
  10 in total

1.  AnkG hemizygous mice present cognitive impairment and elevated anxiety/depressive-like traits associated with decreased expression of GABA receptors and postsynaptic density protein.

Authors:  Cui Liu; Ling Zhang; Jie Wu; Xiaolong Sui; Yanfeng Xu; Lan Huang; Yunlin Han; Hua Zhu; Yanhong Li; Xiuping Sun; Chuan Qin
Journal:  Exp Brain Res       Date:  2017-08-18       Impact factor: 1.972

2.  Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.

Authors:  Suhas Ganesh; Jose Cortes-Briones; Mohini Ranganathan; Rajiv Radhakrishnan; Patrick D Skosnik; Deepak Cyril D'Souza
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

3.  Baseline prepulse inhibition expression predicts the propensity of developing sensitization to the motor stimulant effects of amphetamine in C57BL/6 mice.

Authors:  Daria Peleg-Raibstein; Jonas Hauser; Luis H Llano Lopez; Joram Feldon; Pascual A Gargiulo; Benjamin K Yee
Journal:  Psychopharmacology (Berl)       Date:  2012-08-17       Impact factor: 4.530

Review 4.  Ascorbic Acid to Manage Psychiatric Disorders.

Authors:  Morgana Moretti; Daiane Bittencourt Fraga; Ana Lúcia S Rodrigues
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

Review 5.  The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.

Authors:  Thomas Steinkellner; Michael Freissmuth; Harald H Sitte; Therese Montgomery
Journal:  Biol Chem       Date:  2011-01       Impact factor: 3.915

6.  The cognitive and behavioral effects of D-amphetamine and nicotine sensitization in adult zebrafish.

Authors:  Madeleine Cleal; Barbara D Fontana; Matthew O Parker
Journal:  Psychopharmacology (Berl)       Date:  2021-05-08       Impact factor: 4.530

7.  Hippocampal CA1 region shows differential regulation of gene expression in mice displaying extremes in behavioral sensitization to amphetamine: relevance for psychosis susceptibility?

Authors:  Nicole A Datson; Niels Speksnijder; Inge E M de Jong; Peter J Steenbergen; Kenneth Vielsted Christensen; Krzysztof Potempa; Jan Torleif Pedersen; Jan Egebjerg; Pekka Kallunki; Erik B Nielsen; E Ronald de Kloet; Michael Didriksen
Journal:  Psychopharmacology (Berl)       Date:  2011-05-03       Impact factor: 4.530

8.  Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light.

Authors:  Alessandra Paparelli; Marta Di Forti; Paul D Morrison; Robin M Murray
Journal:  Front Behav Neurosci       Date:  2011-01-17       Impact factor: 3.558

9.  Mutation of Semaphorin-6A disrupts limbic and cortical connectivity and models neurodevelopmental psychopathology.

Authors:  Annette E Rünker; Colm O'Tuathaigh; Mark Dunleavy; Derek W Morris; Graham E Little; Aiden P Corvin; Michael Gill; David C Henshall; John L Waddington; Kevin J Mitchell
Journal:  PLoS One       Date:  2011-11-21       Impact factor: 3.240

10.  Effects of N-acetylcysteine on amphetamine-induced sensitization in mice.

Authors:  Ana P Herrmann; Roberta Andrejew; Radharani Benvenutti; Clarissa S Gama; Elaine Elisabetsky
Journal:  Braz J Psychiatry       Date:  2017-12-11       Impact factor: 2.697

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.